Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563229 | 0.89 | MYC (0.54) | MYCTSHRMEN1MAPTHTT | |
| SCHEMBL1707844 | 0.87 | CYP3A4 (0.45) | MYCTSHRMEN1MAPTHTT | |
| SCHEMBL19849652 | 0.87 | TSHR (0.53) | MYCTSHRMEN1MAPTHTT | |
| SCHEMBL29634134 | 0.87 | TSHR (0.53) | MYCTSHRMEN1MAPTHTT | |
| SCHEMBL524457 | 0.83 | LMNA (0.53) | MYCTSHRMEN1MAPTKMT2A | |
| SCHEMBL3511612 | 0.81 | LMNA (0.59) | MYCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL28684512 | 0.81 | PTGER1 (0.52) | MYCTSHRMEN1MAPTHTT | |
| SCHEMBL562649 | 0.80 | CHEK1 (0.44) | TSHRMEN1MAPTHTTMAPK10 | |
| SCHEMBL2907419 | 0.80 | REN (0.47) | TSHRMEN1MAPTHTTMAPK10 | |
| SCHEMBL24390974 | 0.80 | TSHR (0.57) | MYCTSHRMEN1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2215068-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2215068-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| EP-2215068-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058237-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058237-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | MYC 1916/4885TSHR 926/4885MEN1 4714/4885 |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | MYC 703/4885TSHR 1637/4885MEN1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.